BRIM Biotechnology Inc.
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing B… Read more
BRIM Biotechnology Inc. (6885) - Total Assets
Latest total assets as of June 2024: NT$1.64 Billion TWD
Based on the latest financial reports, BRIM Biotechnology Inc. (6885) holds total assets worth NT$1.64 Billion TWD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BRIM Biotechnology Inc. - Total Assets Trend (2019–2023)
This chart illustrates how BRIM Biotechnology Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BRIM Biotechnology Inc. - Asset Composition Analysis
Current Asset Composition (December 2023)
BRIM Biotechnology Inc.'s total assets of NT$1.64 Billion consist of 96.3% current assets and 3.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 53.3% |
| Accounts Receivable | NT$0.00 | 0.0% |
| Inventory | NT$0.00 | 0.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$1.34 Million | 0.1% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2023)
This chart illustrates how BRIM Biotechnology Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BRIM Biotechnology Inc.'s current assets represent 96.3% of total assets in 2023, an increase from 19.4% in 2019.
- Cash Position: Cash and equivalents constituted 53.3% of total assets in 2023, down from 77.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 0.1% of total assets.
BRIM Biotechnology Inc. Competitors by Total Assets
Key competitors of BRIM Biotechnology Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
BRIM Biotechnology Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BRIM Biotechnology Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BRIM Biotechnology Inc. is currently not profitable relative to its asset base.
BRIM Biotechnology Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 63.15 | 35.01 | 37.76 |
| Quick Ratio | 63.15 | 35.01 | 37.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.56 Billion | NT$ 685.07 Million | NT$ 826.51 Million |
BRIM Biotechnology Inc. - Advanced Valuation Insights
This section examines the relationship between BRIM Biotechnology Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.57 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 89.2% |
| Total Assets | NT$1.78 Billion |
| Market Capitalization | $87.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values BRIM Biotechnology Inc.'s assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: BRIM Biotechnology Inc.'s assets grew by 89.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BRIM Biotechnology Inc. (2019–2023)
The table below shows the annual total assets of BRIM Biotechnology Inc. from 2019 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | NT$1.78 Billion | +89.22% |
| 2022-12-31 | NT$939.99 Million | +89.73% |
| 2021-12-31 | NT$495.44 Million | +56.15% |
| 2020-12-31 | NT$317.28 Million | -28.83% |
| 2019-12-31 | NT$445.78 Million | -- |